Bergamaschi, R., Capobianco , M., & Ravasio, R. (2024). Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy. AboutOpen, 11(1), 48–56. https://doi.org/10.33393/ao.2024.3078